These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1266 related items for PubMed ID: 25624712

  • 1. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
    Chen LZ, Xin YN, Geng N, Jiang M, Zhang DD, Xuan SY.
    World J Gastroenterol; 2015 Jan 21; 21(3):794-802. PubMed ID: 25624712
    [Abstract] [Full Text] [Related]

  • 2. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.
    Wang CW, Lin HY, Shin SJ, Yu ML, Lin ZY, Dai CY, Huang JF, Chen SC, Li SS, Chuang WL.
    Liver Int; 2011 Oct 21; 31(9):1326-31. PubMed ID: 21745282
    [Abstract] [Full Text] [Related]

  • 3. PNPLA3 I148M polymorphism and progressive liver disease.
    Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S, Valenti L.
    World J Gastroenterol; 2013 Nov 07; 19(41):6969-78. PubMed ID: 24222941
    [Abstract] [Full Text] [Related]

  • 4. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
    Donati B, Motta BM, Pingitore P, Meroni M, Pietrelli A, Alisi A, Petta S, Xing C, Dongiovanni P, del Menico B, Rametta R, Mancina RM, Badiali S, Fracanzani AL, Craxì A, Fargion S, Nobili V, Romeo S, Valenti L.
    Hepatology; 2016 Mar 07; 63(3):787-98. PubMed ID: 26605757
    [Abstract] [Full Text] [Related]

  • 5. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.
    Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, Bugianesi E, Maggioni M, Fracanzani AL, Fargion S, Day CP.
    Hepatology; 2010 Apr 07; 51(4):1209-17. PubMed ID: 20373368
    [Abstract] [Full Text] [Related]

  • 6. The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP).
    Arslanow A, Stokes CS, Weber SN, Grünhage F, Lammert F, Krawczyk M.
    Liver Int; 2016 Mar 07; 36(3):418-26. PubMed ID: 26264356
    [Abstract] [Full Text] [Related]

  • 7. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.
    Park JH, Cho B, Kwon H, Prilutsky D, Yun JM, Choi HC, Hwang KB, Lee IH, Kim JI, Kong SW.
    Liver Int; 2015 Dec 07; 35(12):2537-46. PubMed ID: 26148225
    [Abstract] [Full Text] [Related]

  • 8. PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.
    Karamfilova V, Gateva A, Assyov Y, Alexiev A, Savov A, Yaneva N, Ivanova I, Ivanova-Boyanova R, Ivanova R, Vlahova Z, Mateva L, Kamenov Z.
    J Gastrointestin Liver Dis; 2019 Dec 09; 28(4):433-438. PubMed ID: 31826069
    [Abstract] [Full Text] [Related]

  • 9. Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
    Unalp-Arida A, Ruhl CE.
    Hepatology; 2020 Mar 09; 71(3):820-834. PubMed ID: 31705824
    [Abstract] [Full Text] [Related]

  • 10. Circulating triacylglycerol signatures in nonalcoholic fatty liver disease associated with the I148M variant in PNPLA3 and with obesity.
    Hyysalo J, Gopalacharyulu P, Bian H, Hyötyläinen T, Leivonen M, Jaser N, Juuti A, Honka MJ, Nuutila P, Olkkonen VM, Oresic M, Yki-Järvinen H.
    Diabetes; 2014 Jan 09; 63(1):312-22. PubMed ID: 24009255
    [Abstract] [Full Text] [Related]

  • 11. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
    Jiang ZG, Tapper EB, Kim M, Connelly MA, Krawczyk SA, Yee EU, Herman MA, Mukamal KJ, Lai M.
    J Clin Gastroenterol; 2018 Jan 09; 52(5):444-451. PubMed ID: 28362682
    [Abstract] [Full Text] [Related]

  • 12. Effect of the patatin-like phospholipase domain containing 3 gene (PNPLA3) I148M polymorphism on the risk and severity of nonalcoholic fatty liver disease and metabolic syndromes: A meta-analysis of paediatric and adolescent individuals.
    Li J, Hua W, Ji C, Rui J, Zhao Y, Xie C, Shi B, Yang X.
    Pediatr Obes; 2020 Jun 09; 15(6):e12615. PubMed ID: 32020770
    [Abstract] [Full Text] [Related]

  • 13. The Expression of PNPLA3 Polymorphism could be the Key for Severe Liver Disease in NAFLD in Hispanic Population.
    Martínez LA, Larrieta E, Kershenobich D, Torre A.
    Ann Hepatol; 2020 Jun 09; 16(6):909-915. PubMed ID: 29055919
    [Abstract] [Full Text] [Related]

  • 14. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance.
    Rametta R, Ruscica M, Dongiovanni P, Macchi C, Fracanzani AL, Steffani L, Fargion S, Magni P, Valenti L.
    Eur J Clin Invest; 2014 Jul 09; 44(7):627-33. PubMed ID: 24828988
    [Abstract] [Full Text] [Related]

  • 15. Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea.
    Lee SS, Byoun YS, Jeong SH, Woo BH, Jang ES, Kim JW, Kim HY.
    Dig Dis Sci; 2014 Dec 09; 59(12):2967-74. PubMed ID: 25069572
    [Abstract] [Full Text] [Related]

  • 16. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease.
    Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, Alterio A, Dongiovanni P, Fargion S, Nobili V.
    Hepatology; 2010 Oct 09; 52(4):1274-80. PubMed ID: 20648474
    [Abstract] [Full Text] [Related]

  • 17. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
    Krawczyk M, Jiménez-Agüero R, Alustiza JM, Emparanza JI, Perugorria MJ, Bujanda L, Lammert F, Banales JM.
    Surg Obes Relat Dis; 2016 Dec 09; 12(10):1838-1846. PubMed ID: 27576208
    [Abstract] [Full Text] [Related]

  • 18. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.
    Liu WY, Zheng KI, Pan XY, Ma HL, Zhu PW, Wu XX, Rios RS, Targher G, Byrne CD, Wang XD, Chen YP, Zheng MH.
    J Gastroenterol Hepatol; 2020 Jun 09; 35(6):1057-1064. PubMed ID: 31677195
    [Abstract] [Full Text] [Related]

  • 19. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM, Huang CK, Tu HP, Hwang JC, Chang CY, Yu ML.
    Surg Obes Relat Dis; 2015 Jun 09; 11(4):888-94. PubMed ID: 25240529
    [Abstract] [Full Text] [Related]

  • 20. Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis.
    Banini BA, Kumar DP, Cazanave S, Seneshaw M, Mirshahi F, Santhekadur PK, Wang L, Guan HP, Oseini AM, Alonso C, Bedossa P, Koduru SV, Min HK, Sanyal AJ.
    Hepatology; 2021 Apr 09; 73(4):1290-1306. PubMed ID: 33131062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.